MORF News and Press, Morphic Holding Inc. From 04/29/23

2023-04-29 08:25:00 ET 89bio (NASDAQ: ETNB) , Karuna Therapeutics (NASDAQ: KRTX) , and Morphic Therapeutics (NASDAQ: MORF) are clinical-stage biotech companies that make attractive buyout targets. Their financial positions may not be great, as they all have littl...

2023-04-25 22:20:34 ET Summary Positive Phase 2a data: MORF-057 demonstrated a statistically significant reduction in RHI score and a clinical remission rate of 25.7% (mMCS), supporting our bullish thesis on Morphic Therapeutic. Promising safety results: The absence of serious saf...

2023-04-25 13:24:38 ET For further details see: Morphic Holding down 10% despite bottom line earnings beat

2023-04-25 10:06:07 ET Gainers: Baudax Bio ( BXRX ) +48% . Petros Pharmaceuticals ( PTPI ) +48% . Morphic Holding ( MORF ) +22% . Arrowhead Pharmaceuticals ( ARWR ) +17% . Medpace Holdings ( MEDP ) +17% . Losers: Trac...

2023-04-25 08:56:00 ET Morphic press release ( NASDAQ: MORF ): Q1 GAAP EPS of $0.90 beats by $1.71 . Revenue of $0.5M (-79.0% Y/Y) misses by $1.66M . As of March 31, 2023, Morphic had cash, cash equivalents and marketable securities of $421 million, compared to...

2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) +74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) +34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) +32% . ZeroFox ...

2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) -74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) -34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) -32% . ZeroFox ...

2023-04-25 07:35:55 ET Morphic Holding ( NASDAQ: MORF ) added ~38% pre-market Tuesday after announcing that its lead candidate MORF-057 reached the primary endpoint in a mid-stage trial for adults with ulcerative colitis (UC). The EMERALD-1 Phase 2a trial enrolled 35 patient...

-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical remission by Modified Mayo Clinic Score (mMCS)- -MORF-057 generally well tolerated with ...

-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed- -EMERALD-2 Phase 2b Trial of MORF-057 progressing on track- ...